{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-25-001513","form_type":"8-K","ticker":"INKT","cik":"0001840229","company_name":"MiNK Therapeutics, Inc.","filed_at":"2025-03-18T23:59:59+00:00","discovered_at":"2026-05-14T18:03:05.209017+00:00","generated_at":"2026-05-24T14:29:01.132827+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"MiNK Therapeutics reports FY2024 net loss of $10.8M, improved from $22.5M in 2023","bullets":["Net loss for FY2024 was $10.8M ($2.86/diluted share) vs $22.5M ($6.54/share) in 2023.","Cash and cash equivalents at Dec 31, 2024 were $4.6M, up from $3.4M at year-end 2023.","Cash used in operations for FY2024 was $9.6M, compared to $15.8M in 2023.","Clinical progress: AgenT-797 Phase 2 gastric cancer trial enrolling; ARDS data showed ~80% survival in VV ECMO patients.","Raised $5.8M in private financing in 2024; collaboration with Autonomous Therapeutics for RNA-iNKT therapies."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-25-001513","json":"https://secwatch.observer/filing/0001171843-25-001513.json","markdown":"https://secwatch.observer/filing/0001171843-25-001513.md","text":"https://secwatch.observer/filing/0001171843-25-001513.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1840229/000117184325001513/0001171843-25-001513-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1840229/000117184325001513/f8k_031825.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T14:29:01.132827+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}